TRANK1

Summary

TRANK1 (tetratricopeptide repeat and ankyrin repeat containing 1, HGNC:29011) is a protein-coding gene on chromosome 3p22.2, encoding TPR and ankyrin repeat-containing protein 1 (O15050).

At a glance

• GWAS associations: 36
• Clinical variants (ClinVar): 499 total
• Phenotypes (HPO): 35
• MANE Select transcript: NM_001329998

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29011
Approved symbol	TRANK1
Name	tetratricopeptide repeat and ankyrin repeat containing 1
Location	3p22.2
Locus type	gene with protein product
Status	Approved
Aliases	LBA1, KIAA0342
Ensembl gene	ENSG00000168016
Ensembl biotype	protein_coding
OMIM	619316
Entrez	9881

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 3 protein_coding, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000429976, ENST00000463764, ENST00000463984, ENST00000643881, ENST00000645898, ENST00000646436, ENST00000646897

RefSeq mRNA: 2 — MANE Select: NM_001329998 NM_001329998, NM_014831

CCDS: CCDS46789, CCDS87061

Canonical transcript exons

ENST00000645898 — 24 exons

Exon	Start	End
ENSE00001077136	36842622	36842710
ENSE00001119405	36830873	36833919
ENSE00001119406	36829564	36829662
ENSE00001195523	36852146	36852345
ENSE00001505825	36834762	36834907
ENSE00001505826	36838372	36838504
ENSE00001505832	36851719	36851856
ENSE00001683208	36838613	36838716
ENSE00003542167	36846248	36846404
ENSE00003552746	36858718	36858894
ENSE00003555268	36864319	36864480
ENSE00003585671	36847200	36847346
ENSE00003610118	36860906	36861160
ENSE00003646146	36899109	36899259
ENSE00003656342	36855173	36858049
ENSE00003662970	36895640	36895758
ENSE00003665198	36892901	36892984
ENSE00003678969	36892202	36892340
ENSE00003681562	36889829	36889960
ENSE00003689776	36874126	36874296
ENSE00003759775	36903149	36903275
ENSE00003815048	36826819	36828375
ENSE00003817331	36908323	36908454
ENSE00003824632	36944787	36945054

Expression profiles

Bgee: expression breadth ubiquitous, 198 present calls, max score 93.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.9486 / max 268.1598, expressed in 1589 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41663	5.2775	869
41669	2.2209	1006
41668	1.6931	704
41667	1.4781	841
41662	0.2791	98

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	93.67	gold quality
cerebellar hemisphere	UBERON:0002245	93.36	gold quality
cerebellar cortex	UBERON:0002129	93.24	gold quality
left uterine tube	UBERON:0001303	92.86	gold quality
cerebellum	UBERON:0002037	91.51	gold quality
jejunal mucosa	UBERON:0000399	89.90	gold quality
body of uterus	UBERON:0009853	87.41	gold quality
right uterine tube	UBERON:0001302	87.03	gold quality
endocervix	UBERON:0000458	86.97	gold quality
blood	UBERON:0000178	86.64	gold quality
descending thoracic aorta	UBERON:0002345	86.45	gold quality
granulocyte	CL:0000094	86.39	gold quality
rectum	UBERON:0001052	85.94	gold quality
ileal mucosa	UBERON:0000331	85.82	gold quality
gall bladder	UBERON:0002110	85.61	gold quality
right coronary artery	UBERON:0001625	85.44	gold quality
vermiform appendix	UBERON:0001154	84.25	gold quality
left ovary	UBERON:0002119	84.12	gold quality
thoracic aorta	UBERON:0001515	84.09	gold quality
right ovary	UBERON:0002118	84.08	gold quality
ascending aorta	UBERON:0001496	84.01	gold quality
right frontal lobe	UBERON:0002810	83.75	gold quality
mucosa of transverse colon	UBERON:0004991	83.48	gold quality
bone marrow cell	CL:0002092	83.39	gold quality
ectocervix	UBERON:0012249	83.08	gold quality
small intestine Peyer’s patch	UBERON:0003454	83.03	gold quality
paraflocculus	UBERON:0005351	82.76	gold quality
lymph node	UBERON:0000029	82.74	gold quality
muscle layer of sigmoid colon	UBERON:0035805	82.74	gold quality
cerebellar vermis	UBERON:0004720	82.51	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.79

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

97 targeting TRANK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-1184	99.99	68.19	1458
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-497-5P	99.92	71.83	2674

Literature-anchored findings (GeneRIF, showing 5)

• The results of this study suggested that significant novel association signals near the genes TRANK1 and provide supportive evidence for the previously reported association signals near ANK3 and within the 3p21.1 locus. (PMID:22182935)
• Independent replications and integrative analyses confirm TRANK1 as a susceptibility gene for bipolar disorder. (PMID:32791513)
• Kleine-Levin syndrome is associated with birth difficulties and genetic variants in the TRANK1 gene loci. (PMID:33737391)
• Impaired blood-brain barrier in the microbiota-gut-brain axis: Potential role of bipolar susceptibility gene TRANK1. (PMID:34014031)
• New Evidence of Gut Microbiota Involvement in the Neuropathogenesis of Bipolar Depression by TRANK1 Modulation: Joint Clinical and Animal Data. (PMID:34992606)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Trank1	ENSMUSG00000062296
rattus_norvegicus	Trank1	ENSRNOG00000021091
drosophila_melanogaster	CG31038	FBGN0051038
drosophila_melanogaster	lmgB	FBGN0085470

Paralogs (2): FAM89B (ENSG00000176973), FAM89A (ENSG00000182118)

Protein

Protein identifiers

TPR and ankyrin repeat-containing protein 1 — O15050 (reviewed: O15050)

Alternative names: Lupus brain antigen 1 homolog

All UniProt accessions (6): A0A096LPF5, A0A2R8Y7N6, A0A2R8Y890, O15050, A0A2R8Y8A3, A0A2R8YEM9

UniProt curated annotations — full annotation on UniProt →

RefSeq proteins (2): NP_001316927, NP_055646 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR019734	TPR_rpt	Repeat
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR039904	TRANK1	Family

UniProt features (22 total): repeat 10, region of interest 3, compositionally biased region 3, sequence variant 3, chain 1, coiled-coil region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for O15050 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 212 (showing top): MODULE_45, GOZGIT_ESR1_TARGETS_DN, CAIRO_HEPATOBLASTOMA_CLASSES_DN, chr3p22, DAUER_STAT3_TARGETS_DN, MODULE_60, SCHLOSSER_SERUM_RESPONSE_UP, PARENT_MTOR_SIGNALING_UP, LEIN_NEURON_MARKERS, MODULE_15, EBNA1BP2_TARGET_GENES, MIR340_5P, GSE10094_LCMV_VS_LISTERIA_IND_EFF_CD4_TCELL_DN, MIR1297, MIR15A_5P

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

898 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRANK1	TENM4	Q6N022	644
TRANK1	MAD1L1	Q9Y6D9	624
TRANK1	SYNE1	Q8NF91	589
TRANK1	LMAN2L	Q9H0V9	549
TRANK1	CACNB2	Q08289	521
TRANK1	ITIH3	Q06033	509
TRANK1	DAOA	P59103	508
TRANK1	CACNA1C	Q13936	486
TRANK1	RASGRP3	Q8IV61	447
TRANK1	ITIH4	Q14624	444
TRANK1	ANK3	Q12955	437
TRANK1	NCAN	O14594	435
TRANK1	VRK2	Q86Y07	435
TRANK1	NT5C2	P49902	432
TRANK1	TANC1	Q9C0D5	416

IntAct

5 interactions, top by confidence:

A	B	Type	Score
CBX2	TRANK1	psi-mi:“MI:0914”(association)	0.350
DDX6	RPSA2	psi-mi:“MI:2364”(proximity)	0.270
DISC1	TRANK1	psi-mi:“MI:0915”(physical association)	0.000
purE	TRANK1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (8): TRANK1 (Affinity Capture-MS), TRANK1 (Affinity Capture-MS), TRANK1 (Affinity Capture-RNA), TRANK1 (Affinity Capture-MS), TRANK1 (Cross-Linking-MS (XL-MS)), TRANK1 (Affinity Capture-RNA), TRANK1 (Affinity Capture-MS), TRANK1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0A6YYL3, A0JP26, A2A2Z9, A2RUR9, A6NC57, A6NI47, A6QR20, A8MYB1, A9JSR5, A9ZSY0, B2RU33, B7ZQJ9, F1M5M3, H3BUK9, O15050, P51954, P98182, Q19UN5, Q4UJ75, Q501X2, Q5CZ79, Q5DW34, Q5SQ80, Q5TYW2, Q5VUR7, Q66HB6, Q6NSI1, Q6S545, Q6S5H5, Q6S8J7, Q71S21, Q7TPV2, Q7TSC3, Q7ZT11, Q80X59, Q811D2, Q86Y13, Q86YR6, Q8IVF6, Q8IYA2

Diamond homologs: O15050, Q8BV79, A6ZRW3, F8RP11, O13797, O14217, O16259, O35814, O54981, P07213, P15705, P25407, P31948, P38825, P53041, P53042, Q12118, Q3ZBZ8, Q43468, Q49AM3, Q4R8N7, Q54DA8, Q5WA76, Q5XEP2, Q5ZKQ3, Q60676, Q60864, Q68FQ7, Q7ZWU1, Q80XJ3, Q8BW49, Q8ILC1, Q95LY5, Q96AY4, Q9D4H7, Q9D706, Q9H6T3, Q9H892, Q9HGM9, Q9QYI3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

499 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	434
Likely benign	40
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4744 predictions. Top by Δscore:

Variant	Effect	Δscore
3:36828375:CCTG:C	acceptor_loss	1.0000
3:36828376:C:CA	acceptor_loss	1.0000
3:36829559:CTTA:C	donor_loss	1.0000
3:36829561:TACCT:T	donor_loss	1.0000
3:36829562:A:AC	donor_gain	1.0000
3:36829562:A:C	donor_loss	1.0000
3:36829562:ACCTT:A	donor_gain	1.0000
3:36829563:C:CC	donor_gain	1.0000
3:36829563:C:G	donor_loss	1.0000
3:36829563:CCTT:C	donor_gain	1.0000
3:36829563:CCTTC:C	donor_gain	1.0000
3:36829566:T:A	donor_gain	1.0000
3:36829658:CTCCG:C	acceptor_gain	1.0000
3:36829660:CCG:C	acceptor_gain	1.0000
3:36829661:CG:C	acceptor_gain	1.0000
3:36829661:CGC:C	acceptor_gain	1.0000
3:36829662:GC:G	acceptor_loss	1.0000
3:36829663:C:CA	acceptor_loss	1.0000
3:36829663:C:CC	acceptor_gain	1.0000
3:36829666:C:CT	acceptor_gain	1.0000
3:36829667:A:T	acceptor_gain	1.0000
3:36829673:C:CT	acceptor_gain	1.0000
3:36829674:A:T	acceptor_gain	1.0000
3:36830868:CTTA:C	donor_loss	1.0000
3:36830870:TACCG:T	donor_loss	1.0000
3:36830871:A:C	donor_loss	1.0000
3:36830888:T:TA	donor_gain	1.0000
3:36833915:CATAC:C	acceptor_gain	1.0000
3:36833916:ATAC:A	acceptor_gain	1.0000
3:36833917:TAC:T	acceptor_gain	1.0000

AlphaMissense

19698 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:36851775:C:G	A1567P	1.000
3:36842666:A:G	W1702R	0.999
3:36842666:A:T	W1702R	0.999
3:36846379:A:G	L1643P	0.999
3:36846388:A:G	L1640P	0.999
3:36847334:A:G	W1590R	0.999
3:36847334:A:T	W1590R	0.999
3:36851758:A:C	F1572L	0.999
3:36851758:A:T	F1572L	0.999
3:36851760:A:G	F1572L	0.999
3:36851769:C:G	G1569R	0.999
3:36851771:T:A	K1568I	0.999
3:36855184:C:A	R1469M	0.999
3:36855294:G:C	F1432L	0.999
3:36855294:G:T	F1432L	0.999
3:36855296:A:G	F1432L	0.999
3:36855318:C:A	Q1424H	0.999
3:36855318:C:G	Q1424H	0.999
3:36855322:G:T	A1423D	0.999
3:36855328:T:A	D1421V	0.999
3:36855328:T:C	D1421G	0.999
3:36855328:T:G	D1421A	0.999
3:36855329:C:G	D1421H	0.999
3:36855402:T:A	Q1396H	0.999
3:36855402:T:G	Q1396H	0.999
3:36855409:T:A	E1394V	0.999
3:36855409:T:G	E1394A	0.999
3:36855412:T:G	D1393A	0.999
3:36846371:C:G	A1646P	0.998
3:36851747:A:G	L1576P	0.998

dbSNP variants (sampled 300 via entrez): RS1000004131 (3:36850443 C>A,G,T), RS1000046533 (3:36934409 C>G), RS1000097432 (3:36864590 G>A), RS1000128811 (3:36902930 C>T), RS1000184508 (3:36860575 G>A,C), RS1000201884 (3:36911474 A>C,T), RS1000217388 (3:36889628 T>C), RS1000220975 (3:36908936 T>A), RS1000225423 (3:36943677 G>A), RS1000230669 (3:36826726 T>A,C), RS1000254433 (3:36869760 T>C), RS1000260444 (3:36827041 G>A), RS1000315688 (3:36921957 C>G,T), RS1000316723 (3:36827221 G>C,T), RS1000340303 (3:36826990 A>G)

Disease associations

OMIM: gene MIM:619316 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (2): autism (MONDO:0005260), autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

35 total (30 of 35 shown, HPO-id order):

HPO	Term
HP:0000613	Photophobia
HP:0000622	Blurred vision
HP:0000713	Agitation
HP:0000716	Depression
HP:0000737	Irritability
HP:0000739	Anxiety
HP:0000741	Apathy
HP:0000746	Delusion
HP:0000975	Hyperhidrosis
HP:0001289	Confusion
HP:0001350	Slurred speech
HP:0001945	Fever
HP:0001959	Polydipsia
HP:0002018	Nausea
HP:0002167	Abnormal speech pattern
HP:0002300	Mutism
HP:0002315	Headache
HP:0002519	Hypnagogic hallucination
HP:0002591	Polyphagia
HP:0004396	Poor appetite
HP:0007057	Poor hand-eye coordination
HP:0007200	Episodic hypersomnia
HP:0008762	Repetitive compulsive behavior
HP:0010534	Transient global amnesia
HP:0012658	Abnormal brain FDG positron emission tomography
HP:0025233	Sleep paralysis
HP:0030221	Sweet craving
HP:0031217	Hot flashes
HP:0031249	Parageusia
HP:0034004	Parosmia

GWAS associations

36 associations (top):

Study	Trait	p-value
GCST001241_18	Bipolar disorder	9.000000e-06
GCST001358_4	Bipolar disorder	1.000000e-12
GCST001715_3	Bipolar disorder with mood-incongruent psychosis	1.000000e-07
GCST002295_1	Schizophrenia or bipolar disorder	4.000000e-07
GCST002295_7	Schizophrenia or bipolar disorder	1.000000e-10
GCST002385_6	Bipolar disorder	2.000000e-08
GCST002539_47	Schizophrenia	1.000000e-13
GCST003158_2	Subjective response to lithium treatment	8.000000e-07
GCST003724_2	Bipolar disorder	5.000000e-10
GCST003962_2	Bipolar disorder	2.000000e-10
GCST004139_17	Bipolar disorder	2.000000e-09
GCST004521_90	Autism spectrum disorder or schizophrenia	1.000000e-11
GCST004616_141	Platelet distribution width	2.000000e-10
GCST004946_15	Schizophrenia	3.000000e-11
GCST005094_2	Iris color (L* coordinate)	7.000000e-06
GCST006575_3	Takayasu arteritis	5.000000e-06
GCST006611_69	HDL cholesterol	3.000000e-12
GCST006613_77	Triglycerides	5.000000e-08
GCST006629_86	Pulse pressure	6.000000e-15
GCST006803_105	Schizophrenia	9.000000e-11
GCST007201_137	Schizophrenia	4.000000e-11
GCST007201_278	Schizophrenia	2.000000e-12
GCST007565_148	Morning person	1.000000e-13
GCST007576_4	Chronotype	1.000000e-13
GCST008103_178	Bipolar disorder	8.000000e-06
GCST008103_2	Bipolar disorder	6.000000e-12
GCST008115_1	Bipolar I disorder	4.000000e-14
GCST009600_86	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	2.000000e-17
GCST010241_346	Apolipoprotein A1 levels	4.000000e-08
GCST010242_52	HDL cholesterol levels	3.000000e-09

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0007984	platelet component distribution width
EFO:0003949	eye color
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004530	triglyceride measurement
EFO:0005763	pulse pressure measurement
EFO:0008328	chronotype measurement
EFO:0009963	bipolar I disorder
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004327	electrocardiography

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	3
epigallocatechin gallate	decreases expression, increases expression, affects cotreatment	2
Air Pollutants	increases abundance, decreases expression, affects cotreatment, affects expression, affects oxidation	2
Nickel	decreases expression, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Tretinoin	increases expression	2
sotorasib	affects cotreatment, increases expression	1
alpha-pinene	affects cotreatment, affects expression, affects oxidation, increases abundance	1
bisphenol A	increases expression	1
trichostatin A	affects expression	1
arsenite	decreases reaction, affects binding	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	increases methylation	1
methacrylaldehyde	increases abundance, affects cotreatment, affects expression, affects oxidation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
nutlin 3	affects cotreatment, increases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, increases expression	1
incobotulinumtoxinA	increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
Temozolomide	increases expression	1
Acrolein	affects cotreatment, affects expression, affects oxidation, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases abundance, increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1I8	Abcam A-549 TRANK1 KO 1	Cancer cell line	Male
CVCL_B2QS	Abcam A-549 TRANK1 KO 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms